This webinar is hosted by the African Academy of Sciences (The AAS) Clinical Trials Community (CTC) programme.
The meeting will bring together, a range of stakeholders including African clinical trialists, regulators, ethicists and trial sponsors and will include a one-hour discussion from a panel comprising of representatives from the Bill & Melinda Gates Foundation, Ghana FDA, WHO AVAREF, FHI Clinical and Novartis.
The panelists will discuss among other things:
1. Importance of robust and efficient regulatory and ethics bodies for
the clinical trial landscape.
2. Role of WHO African Vaccine Regulatory Forum (AVAREF)
3. Role of CTC platform in enhancing collaborations and promoting efficiency through shared regulatory and ethics information.
The meeting will culminate in a demonstration of the CTC platform and how you can join the community by profiling yourself and your National Regulatory Authority or Institutional Review Board to increase your visibility and engagement with various stakeholders.
Please RSVP by Monday, September 14, 2020.
FHI Clinical Presenter
Vice President, Global Strategy at FHI Clinical
With more than sixteen years of experience in clinical research monitoring and management, Ghiorghis Belai serves as FHI Clinical’s Vice President, Global Strategy. In this role, Belai is responsible for managing FHI Clinical’s relationships with sponsors and sites, and he works on project feasibility to ensure optimal implementation of trials.
Belai previously served as Director of Clinical Operations for FHI 360, where he managed the clinical research unit based in Nairobi, Kenya, while supervising and mentoring the FHI 360 Africa Regional Clinical Research Unit. In this role, Belai was responsible for reviewing study protocols, coordinating study implementation of multi-center and multi-country trials in Africa, and ensuring that studies adhered to protocol requirements and applicable regulations and guidelines. With a background in clinical research, Belai has also worked as a clinical research associate for PharmaNet Development Group, Inc., and PPD, where he participated in multiple multi-center clinical research studies, assisted with project data clinical review and management, and presented at investigator meetings for assigned studies. In addition, Belai monitored sites according to applicable standard operating procedures and Food and Drug Administration guidelines and reviewed case report forms for adherence to protocol requirements.
Belai holds a bachelor’s degree in Clinical Laboratory Science from the University of Louisiana at Monroe and a master’s degree in Clinical Research from the University of Liverpool.
